Emergency Medicine News - Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection-Sponsored by Thermo Fisher Scientific cover logo

Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection

30m · Emergency Medicine News - Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection-Sponsored by Thermo Fisher Scientific · 09 Jun 18:41

Sherrie Smartt, RN, MSN, Medical Director of Clinical Studies and Regulatory Affairs Manager for Thermo Fisher Diagnostic Biomarkers, interviews Eric H. Gluck MD, Director of Critical Care Services at Swedish Covenant Hospital, Professor of Medicine at Finch University of Health Sciences, an author of the foundation for the MOSES trial, which expanded the procalcitonin FDA claim, and a member on PCT-Guided Antibiotic Therapy in Hospitals, and Mike Broyles, PharmD, a hospital pharmacy and laboratory director focusing on antimicrobial stewardship and consultant for a large IDN as pharmacy advisory chairman for more than 25 years, who is also on the Board for Thermo Fisher Scientific, Roche Diagnostics, bioMerieux, Fujirebio, Abbott Diagnostics, and ICNet, and a member on PCT-Guided Antibiotic Therapy in Hospitals.

Sponsored by Thermo Fisher Scientific

The episode Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection from the podcast Emergency Medicine News - Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection-Sponsored by Thermo Fisher Scientific has a duration of 30:39. It was first published 09 Jun 18:41. The cover art and the content belong to their respective owners.

More episodes from Emergency Medicine News - Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection-Sponsored by Thermo Fisher Scientific

Procalcitonin: Risk Assessment in COVID-19 Bacterial Co-Infection

Sherrie Smartt, RN, MSN, Medical Director of Clinical Studies and Regulatory Affairs Manager for Thermo Fisher Diagnostic Biomarkers, interviews Eric H. Gluck MD, Director of Critical Care Services at Swedish Covenant Hospital, Professor of Medicine at Finch University of Health Sciences, an author of the foundation for the MOSES trial, which expanded the procalcitonin FDA claim, and a member on PCT-Guided Antibiotic Therapy in Hospitals, and Mike Broyles, PharmD, a hospital pharmacy and laboratory director focusing on antimicrobial stewardship and consultant for a large IDN as pharmacy advisory chairman for more than 25 years, who is also on the Board for Thermo Fisher Scientific, Roche Diagnostics, bioMerieux, Fujirebio, Abbott Diagnostics, and ICNet, and a member on PCT-Guided Antibiotic Therapy in Hospitals.

Sponsored by Thermo Fisher Scientific